Trial Profile
Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs LCL 161 (Primary) ; Topotecan (Primary) ; Granulocyte colony-stimulating factors
- Indications Carcinoma; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer
- Focus Adverse reactions
- 17 Aug 2021 Status changed from active, no longer recruiting to discontinued.
- 12 Aug 2020 Planned End Date changed from 27 Jul 2020 to 30 Jul 2021.
- 12 Aug 2020 Planned primary completion date changed from 27 Jul 2020 to 30 Jul 2021.